The major findings of this study were: (1) Injection of recombinant CXCL12 reduced the formation of collagen and reduced collagen fiber width in a pre-clinical cat model of I/R-induced tubulointerstitial fibrosis; and (2) Kidney injection of recombinant CXCL12 was safe and feasible as local treatment in cats with early stages of CKD. The gene discussed is CXCL12; the disease is chronic kidney disease.